Octreotide in gastrointestinal motility disorders

Area of Science:

• Gastroenterology
• Pharmacology
• Neurogastroenterology

Background:

• Scleroderma is associated with chaotic intestinal motility and gastrointestinal symptoms.
• Octreotide is a somatostatin analog with known effects on gastrointestinal function.
• Rectal hypersensitivity and urgency are common in irritable bowel syndrome.

Purpose of the Study:

• To investigate the effects of octreotide on intestinal motility and plasma motilin in normal subjects and scleroderma patients.
• To evaluate the clinical efficacy of long-term octreotide treatment in scleroderma patients.
• To assess octreotide's impact on rectal distension perception and sensory pathways in healthy volunteers and IBS patients.

Main Methods:

• Single octreotide injections and 3-week subcutaneous treatment in scleroderma patients.
• Assessment of intestinal motility, plasma motilin, and breath hydrogen.
• Double-blind, placebo-controlled study of octreotide in healthy volunteers measuring rectal distension perception and electroencephalographic responses.

Main Results:

• Octreotide normalized chaotic intestinal motility in scleroderma patients, making it coordinated and aborally directed.
• Scleroderma patients experienced reduced abdominal pain, nausea, vomiting, bloating, and improved bacterial overgrowth.
• Octreotide decreased the perception of rectal distension in healthy volunteers by inhibiting sensory afferent pathways, with similar effects in IBS patients.

Conclusions:

• Octreotide effectively modulates intestinal motility and alleviates symptoms in scleroderma.
• Octreotide reduces rectal sensory perception, suggesting a role in managing conditions like irritable bowel syndrome with rectal urgency.
• The drug's effects appear mediated by inhibition of sensory pathways rather than motor pathways.